Compare Elastic NV (ESTC) vs Moderna, Inc. (MRNA) Price & Performance

Elastic N.V. (ESTC) trades at $77.16, up 1.1% with a bullish technical outlook. The stock shows strong profitability with a 76.07% gross margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights include a collaboration with OpenAI and recognition as a leader in Gartner's Magic Quadrant for Observability Platforms. Institutional activity is mixed, with Amundi increasing its stake while BNY Mellon reduced its position.

The outlook is positive, supported by earnings momentum and strategic partnerships, but risks include high valuation multiples and a recent legal investigation. Analyst consensus is bullish with a $74.21 price target, though the current price exceeds this, indicating potential near-term consolidation. Revenue growth and AI integration present key opportunities for long-term investors.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.